Iconovo to present at Redeye Life Science Day November 23

Johan Wäborg, CEO, will present Iconovo at Redeye Life Science Day. Learn more about why you should invest in Iconovo and get excited by our vision to…

Busy days for Iconovo at BIO-Europe

Iconovo had three hectic days at BIO-Europe, with a large number of meetings with potential partners. The company especially highlighted their latest innovation,…

Iconovo and Arcede Pharma take the next step in the development of a new treatment for COPD

Iconovo AB (publ), which develops complete inhalation products for a global market, and Arcede Pharma, which develops inhalation treatments for COPD and…

Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone

Iconovo announces that the clinical phase I study of oxytocin in the company's inhaler ICOone that was initiated earlier this year in Melbourne, Australia,…

Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies

Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies Iconovo has entered into a feasibility…

Iconovo Accelerator Program

On June 1st, 2023 Iconovo launched its Iconovo Accelerator to facilitate the opportunities for the company’s customers to obtain EU funding for the development…

Stora affärsmöjligheter när patent värda 100 miljarder löper ut

Iconovo tillverkar inhalatorer för olika typer av läkemedel. I en bransch där stora läkemedelsbolag dominerar är Iconovo ett av få bolag i världen…

PRESSRELEASE New patent for ICOone

PRESSRELEASE 230126:  The European Patent Office EPO intends to approve Iconovo's patent application for the inhaler platform ICOone® (Communication…

Iconovo i Penserpodden

Penserpodden är en podd om aktier, börs och marknad där några av våra mest framstående förvaltare och analytiker går igenom allt från både…

Johan Wäborg, VD i Sveriges Radio om samarbete för bättre läkemedel